TRADES
Latest Trades
99
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKK 14 Dec 2022 Sell PACB PACIFIC BIOSCIENCES OF CALIF 27,394 0.0038
ARKK 13 Dec 2022 Sell PACB PACIFIC BIOSCIENCES OF CALIF 62,820 0.0093
ARKK 9 Dec 2022 Sell PACB PACIFIC BIOSCIENCES OF CALIF 224,167 0.0309
ARKG 22 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 277,116 0.0581
ARKK 22 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 296,053 0.0202
ARKG 17 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 162,549 0.0400
ARKK 17 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 177,784 0.0138
ARKG 16 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 82,913 0.2935
ARKK 16 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 90,803 0.0666
ARKG 11 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 23,651 0.0059
ARKK 11 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 26,369 0.0020
ARKG 10 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 144,657 0.0369
ARKK 10 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 161,682 0.0126
ARKG 4 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 98,284 0.0192
ARKK 4 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 113,483 0.0064
ARKG 13 Jun 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 96,742 0.0168
ARKK 13 Jun 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 105,390 0.0000
ARKG 23 Feb 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 46,576 0.0136
ARKK 23 Feb 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 44,297 0.0042
ARKG 18 Jan 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 39,900 0.0105
ARKK 18 Jan 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 125,500 0.0106
ARKG 14 Jan 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 48,600 0.0150
ARKK 14 Jan 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 153,200 0.0147
ARKG 11 Jan 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 19,000 0.0060
ARKK 11 Jan 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 61,500 0.0062
ARKK 27 Dec 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 60,066 0.0073
ARKG 6 Dec 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 126,220 0.0500
ARKK 6 Dec 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 65,806 0.0100
ARKK 30 Nov 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 161,674 0.0200
ARKK 29 Nov 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 419,669 0.0523
ARKK 26 Nov 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 61,998 0.0100
ARKK 24 Nov 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 492,565 0.0622
ARKG 23 Nov 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 352,967 0.1393
ARKK 9 Nov 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 254,056 0.0343
ARKG 8 Nov 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 19,950 0.0078
ARKG 3 Nov 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 54,000 0.0199
ARKK 2 Nov 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 125,658 0.0157
ARKK 29 Oct 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 119,183 0.0146
ARKK 28 Oct 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 2,450 0.0003
ARKK 27 Oct 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 522,914 0.0618
ARKK 26 Oct 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 16,618 0.0020
ARKK 25 Oct 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 78,058 0.0094
ARKG 22 Oct 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 267,412 0.0947
ARKG 21 Oct 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 17,860 0.0063
ARKK 6 Oct 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFOR 57,511 0.0100
ARKG 5 Oct 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 124,974 0.0456
ARKK 5 Oct 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 658,606 0.0868
ARKK 1 Oct 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 371,100 0.0491
ARKG 29 Sep 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 170,327 0.0587
ARKG 28 Sep 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 80,479 0.0265
ARKK 3 Aug 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 190,000 0.0263
ARKG 2 Aug 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 96,000 0.0349
ARKK 2 Aug 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 756,850 0.1063
ARKK 30 Jul 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 263,353 0.0370
ARKK 29 Jul 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 9,616 0.0013
ARKG 27 Jul 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 466,891 0.1597
ARKG 26 Jul 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 109,825 0.0378
ARKK 26 Jul 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 255,299 0.0334
ARKK 23 Jul 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 265,173 0.0345
ARKK 22 Jul 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 516,093 0.0695
ARKG 21 Jul 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 265,614 0.0874
ARKK 21 Jul 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 101,948 0.0141
ARKG 20 Jul 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 354,388 0.1174
ARKK 8 Jun 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 15,000 0.0020
ARKK 4 Jun 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 57,325 0.0073
ARKK 3 Jun 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 40,000 0.0051
ARKK 21 May 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 5,000 0.0006
ARKK 20 May 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 7,496 0.0009
ARKK 18 May 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 2,124 0.0002
ARKK 17 May 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 184,189 0.0216
ARKK 14 May 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 25,469 0.0030
ARKK 13 May 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 287,624 0.0355
ARKK 11 May 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 112,867 0.0127
ARKG 19 Feb 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 73,715 0.0300
ARKG 18 Feb 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 224,750 0.0792
ARKG 16 Feb 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 17,049 0.0064
ARKG 11 Feb 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 667,121 0.2699
ARKG 1 Feb 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 210,508 0.0645
ARKG 29 Jan 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 17,304 0.0100
ARKG 28 Jan 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 72,827 0.0200
ARKG 26 Jan 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 21,269 0.0068
ARKG 25 Jan 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 60,401 0.0188
ARKG 20 Jan 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 264,450 0.0917
ARKG 19 Jan 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 121,424 0.0500
ARKG 14 Jan 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 85,273 0.0300
ARKG 13 Jan 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 217,015 0.0800
ARKG 12 Jan 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 379,117 0.1393
ARKG 11 Jan 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 626,054 0.2381
ARKK 7 Jan 2021 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 299,238 0.0479
ARKG 29 Oct 2020 Sell PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 146,100 0.0680
ARKK 21 Sep 2020 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 94,744 0.0090
ARKK 18 Sep 2020 Buy PACB PACIFIC BIOSCIENCES OF CALIFOR 862,410 0.0800
ARKK 17 Sep 2020 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 906,676 0.0845
ARKK 16 Sep 2020 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 407,749 0.0379
ARKK 15 Sep 2020 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 114,207 0.0097
ARKK 14 Sep 2020 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 110,085 0.0098
ARKK 11 Sep 2020 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 74,700 0.0067
ARKK 10 Sep 2020 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 44,123 0.0039
ARKK 9 Sep 2020 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 5,154 0.0004
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.